Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Regina García-Delgado, Dunia de Miguel, Alicia Bailén, José Ramón González, Joan Bargay, José F. Falantes, Rafael Andreu, Fernando Ramos, Mar Tormo, Salut Brunet, Antonio Figueredo, Javier Casaño, Ángeles Medina, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. © 2014 The Authors.
Original languageEnglish
Pages (from-to)744-750
JournalLeukemia Research
Volume38
Issue number7
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Acute myeloid leukemia
  • Azacitidine
  • Dosing schedules
  • Myelodysplastic syndromes
  • Overall survival
  • Safety

Fingerprint Dive into the research topics of 'Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this